Author

M. V. C. dela Cerna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

B. G. Patty· 1 shared C. N. Smith· 1 shared D. Lee· 1 shared D. R. Rivas· 1 shared G. M. Bennett· 1 shared J. S. Blackburn· 1 shared J. Starczewski· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. G. Patty

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintJul 31, 2023

Identification of putative druggable pockets in PRL3, a significant oncology target, using in silico analysis

G. M. Bennett, J. Starczewski, M. V. C. dela Cerna

This study identifies druggable pockets in PRL3 using computational methods to guide drug discovery for oncology targets.

DOI 10.1101/2023.07.31.551065

protein structuredeep learning

𝕏 PostBluesky

Cancer BiologybioRxivMay 24, 2020

A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3)

D. R. Rivas, M. V. C. Dela Cerna, C. N. Smith…·J. S. Blackburn

The paper screens FDA-approved drugs to identify inhibitors of PTP4A3 (PRL-3), finding five specific inhibitors and two broad inhibitors that block PRL-3-induced migration without affecting cell viability.

DOI 10.1038/s41598-021-89668-5

humanexperimental assay

𝕏 PostBluesky